Simona Colla, PhD

Peer-Reviewed Articles

1. Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica 108(10):2626-2638, 2023. e-Pub 2023. PMID: 37078252.
2. Montalban-Bravo G, Ma F, Thongon N, Yang H, Gomez IG, Rodriguez-Sevilla JJ, Adema V, Wildeman B, Lockyer P, Kim YJ, Tanaka T, Darbaniyan F, Pancholy S, Zhang G, Al-Atrash G, Dwyer K, Takahashi K, Garcia-Manero G, Kantarjian H, Colla S. Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS -mutated chronic myelomonocytic leukemia. bioRxiv, 2023. e-Pub 2023. PMID: 37066354.
3. Adema V, Ma F, Kanagal-Shamanna R, Thongon N, Montalban-Bravo G, Yang H, Peslak SA, Wang F, Acha P, Sole F, Lockyer P, Cassari M, Maciejewski JP, Visconte V, Gañán-Gómez I, Song Y, Bueso-Ramos C, Pellegrini M, Tan TM, Bejar R, Carew JS, Halene S, Santini V, Al-Atrash G, Clise-Dwyer K, Garcia-Manero G, Blobel GA, Colla S. Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts. Blood Cancer Discov 3(6):554-567, 2022. PMID: 35926182.
4. Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol 9(10):e756-e765, 2022. e-Pub 2022. PMID: 36063832.
5. Li Z, Wang Y, Ganan-Gomez I, Colla S, Do KA. A machine learning-based method for automatically identifying novel cells in annotating single-cell RNA-seq data. Bioinformatics 38(21):4885-4892, 2022. PMID: 36083008.
6. Wei Y, Kanagal-Shamanna R, Zheng H, Bao N, Lockyer PP, Class CA, Darbaniyan F, Lu Y, Lin K, Yang H, Montalban-Bravo G, Ganan-Gomez I, Soltysiak KA, Do KA, Colla S, Garcia-Manero G. Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Leukemia 36(8):2097-2107, 2022. e-Pub 2022. PMID: 35697791.
7. Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(3):557-567, 2022. e-Pub 2022. PMID: 35241842.
8. Thongon N, Ma F, Santoni A, Marchesini M, Fiorini E, Rose A, Adema V, Ganan-Gomez I, Groarke EM, Gutierrez-Rodrigues F, Chen S, Lockyer P, Schneider S, Bueso-Ramos C, Montalban-Bravo G, Class CA, Soltysiak KA, Pellegrini M, Sahin E, Bertuch AA, DiNardo CD, Garcia-Manero G, Young NS, Dwyer K, Colla S. Hematopoiesis under telomere attrition at the single-cell resolution. Nat Commun 12(1):6850, 2021. e-Pub 2021. PMID: 34824242.
9. Chakravarti D, Lee R, Multani AS, Santoni A, Keith Z, Hsu WH, Chang K, Reyes L, Rashid A, Wu CJ, Li J, Zhang J, Shim HS, Chandra K, Deng P, Spring DJ, Nielsen OH, Riis LB, Mayigegowda KK, Blutt SE, Zhang J, Younes M, DuPont A, Thirumurthi S, Vilar E, Estes MK, Colla S, Shroyer NF, DePinho RA. Telomere dysfunction instigates inflammation in inflammatory bowel disease. Proc Natl Acad Sci U S A 118(29), 2021. PMID: 34253611.
10. Nofrini V, Matteucci C, Pellanera F, Gorello P, Di Giacomo D, Lema Fernandez AG, Nardelli C, Iannotti T, Brandimarte L, Arniani S, Moretti M, Gili A, Roti G, Di Battista V, Colla S, Mecucci C. Activating somatic and germline TERT promoter variants in myeloid malignancies. Leukemia 35(1):274-278, 2021. e-Pub 2020. PMID: 32366939.
11. Frenquelli M, Caridi N, Antonini E, Storti F, Viganò V, Gaviraghi M, Occhionorelli M, Bianchessi S, Bongiovanni L, Spinelli A, Marcatti M, Belloni D, Ferrero E, Karki S, Brambilla P, Martinelli-Boneschi F, Colla S, Ponzoni M, DePinho RA, Tonon G. The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation. Leukemia 34(1):257-270, 2020. e-Pub 2019. PMID: 31148590.
12. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv 3(6):922-933, 2019. PMID: 30902805.
13. Wei Y, Zheng H, Bao N, Jiang S, Bueso-Ramos CE, Khoury J, Class C, Lu Y, Lin K, Yang H, Ganan-Gomez I, Starczynowski DT, Do KA, Colla S, Garcia-Manero-G. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood Adv 2(19):2491-2504, 2018. PMID: 30275007.
14. Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget 9(11):9714-9727, 2018. e-Pub 2018. PMID: 29515765.
15. Ong DST, Hu B, Ho YW, Sauvé CG, Bristow CA, Wang Q, Multani AS, Chen P, Nezi L, Jiang S, Gorman CE, Monasterio MM, Koul D, Marchesini M, Colla S, Jin EJ, Sulman EP, Spring DJ, Yung WA, Verhaak RGW, Chin L, Wang YA, DePinho RA. PAF promotes stemness and radioresistance of glioma stem cells. Proc Natl Acad Sci U S A 114(43):E9086-E9095, 2017. e-Pub 2017. PMID: 29073105.
16. Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D'Anca M, Storti P, Samur MK, Ganan-Gomez I, Fulciniti MT, Mistry N, Jiang S, Bao N, Marchica V, Neri A, Bueso-Ramos C, Wu CJ, Zhang L, Liang H, Peng X, Giuliani N, Draetta G, Clise-Dwyer K, Kantarjian H, Munshi N, Orlowski R, Garcia-Manero G, DePinho RA, Colla S. ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell 32(1):88-100.e6, 2017. e-Pub 2017. PMID: 28669490.
17. Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of Achievement of Complete Cytogenetic Response on Outcome in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents. Am J Hematol 92(4):351-358, 2017. e-Pub 2017. PMID: 28076892.
18. Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, Amin S, Molin MD, Ying H, Kwong LN, Colla S, Takahashi K, Ghosh P, Giuliani V, Muller F, Dey P, Jiang S, Garvey J, Liu CG, Zhang J, Heffernan TP, Toniatti C, Fleming JB, Goggins MG, Wood LD, Sgambato A, Agaimy A, Maitra A, Roberts CW, Wang H, Viale A, DePinho RA, Draetta GF, Chin L. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature 542(7641):362-366, 2017. e-Pub 2017. PMID: 28178232.
19. Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, Zhao L, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, DiNardo CD, Colla S, Ravandi F, Zhang J, Huang X, Wu X, Samaniego F, Garcia-Manero G, Futreal PA. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol 18(1):100-111, 2017. e-Pub 2016. PMID: 27923552.
20. Chamseddine AN, Cabrero M, Wei Y, Ganan-Gomez I, Colla S, Takahashi K, Yang H, Bohannan ZS, Garcia-Manero G. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clin Lymphoma Myeloma Leuk 16 Suppl:S67-73, 2016. PMID: 27521329.
21. Cabrero M, Wei Y, Yang H, Ganan-Gomez I, Bohannan Z, Colla S, Marchesini M, Bravo GM, Takahashi K, Bueso-Ramos C, Garcia-Manero G. Down-regulation of EZH2 expression in myelodysplastic syndromes. Leuk Res 44:1-7, 2016. e-Pub 2016. PMID: 26970171.
22. Cabrero M, Yu Y, Verma A, Yang H, Colla S, Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultwood J, Garcia-Manero G, Wei Y. Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. Br J Haematol 173(1):161-5, 2016. e-Pub 2015. PMID: 26105212.
23. Darman RB, Seiler M, Agrawal AA, Lim KH, Peng S, Aird D, Bailey SL, Bhavsar EB, Chan B, Colla S, Corson L, Feala J, Fekkes P, Ichikawa K, Keaney GF, Lee L, Kumar P, Kunii K, MacKenzie C, Matijevic M, Mizui Y, Myint K, Park ES, Puyang X, Selvaraj A, Thomas MP, Tsai J, Wang JY, Warmuth M, Yang H, Zhu P, Garcia-Manero G, Furman RR, Yu L, Smith PG, Buonamici S. Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. Cell Rep 13(5):1033-45, 2015. e-Pub 2015. PMID: 26565915.
24. Colla S, Ong DS, Ogoti Y, Marchesini M, Mistry NA, Clise-Dwyer K, Ang SA, Storti P, Viale A, Giuliani N, Ruisaard K, Ganan Gomez I, Bristow CA, Estecio M, Weksberg DC, Ho YW, Hu B, Genovese G, Pettazzoni P, Multani AS, Jiang S, Hua S, Ryan MC, Carugo A, Nezi L, Wei Y, Yang H, D'Anca M, Zhang L, Gaddis S, Gong T, Horner JW, Heffernan TP, Jones P, Cooper LJ, Liang H, Kantarjian H, Wang YA, Chin L, Bueso-Ramos C, Garcia-Manero G, DePinho RA. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell 27(5):644-57, 2015. PMID: 25965571.
25. Pettazzoni P, Viale A, Shah P, Carugo A, Ying H, Wang H, Genovese G, Seth S, Minelli R, Green T, Huang-Hobbs E, Corti D, Sanchez N, Nezi L, Marchesini M, Kapoor A, Yao W, Francesco ME, Petrocchi A, Deem AK, Scott K, Colla S, Mills GB, Fleming JB, Heffernan TP, Jones P, Toniatti C, DePinho RA, Draetta GF. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Res 75(6):1091-101, 2015. e-Pub 2015. PMID: 25736685.
26. Yang H, Maddipoti S, Quesada A, Bohannan Z, Cabrero Calvo M, Colla S, Wei Y, Estecio M, Wierda W, Bueso-Ramos C, Garcia-Manero G. Analysis of class I and II histone deacetylase gene expression in human leukemia. Leuk Lymphoma 56(12):3426-33, 2015. e-Pub 2015. PMID: 25944469.
27. Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick S, Sekeres MA, List AF, Onida F, Komrokji RS, Tefferi A, Solary E. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J 5:e333, 2015. e-Pub 2015. PMID: 26230957.
28. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, Kost-Alimova M, Muller F, Colla S, Nezi L, Genovese G, Deem AK, Kapoor A, Yao W, Brunetto E, Kang Y, Yuan M, Asara JM, Wang YA, Heffernan TP, Kimmelman AC, Wang H, Fleming JB, Cantley LC, DePinho RA, Draetta GF. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514(7524):628-32, 2014. e-Pub 2014. PMID: 25119024.
29. Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D, Martella E, Lazzaretti M, Mancini C, Agnelli L, Patrene K, Maïga S, Franceschi V, Colla S, Anderson J, Neri A, Amiot M, Aversa F, David Roodman G, Giuliani N. Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia 27(8):1697-706, 2013. e-Pub 2013. PMID: 23344526.
30. Bolzoni M, Donofrio G, Storti P, Guasco D, Toscani D, Lazzaretti M, Bonomini S, Agnelli L, Capocefalo A, Dalla Palma B, Neri A, Nicolini F, Lisignoli G, Russo F, Colla S, Aversa F, Giuliani N. Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells. Leukemia 27(2):451-63, 2013. e-Pub 2012. PMID: 22781592.
31. Genovese G, Ergun A, Shukla SA, Campos B, Hanna J, Ghosh P, Quayle SN, Rai K, Colla S, Ying H, Wu CJ, Sarkar S, Xiao Y, Zhang J, Zhang H, Kwong L, Dunn K, Wiedemeyer WR, Brennan C, Zheng H, Rimm DL, Collins JJ, Chin L. microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. Cancer Discov 2(8):736-49, 2012. e-Pub 2012. PMID: 22750848.
32. Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, Eisenson D, Narurkar R, Deng P, Nezi L, Lee MA, Hu B, Hu J, Sahin E, Ong D, Fletcher-Sananikone E, Ho D, Kwong L, Brennan C, Wang YA, Chin L, DePinho RA. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488(7411):337-42, 2012. PMID: 22895339.
33. Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H, Fletcher-Sananikone E, Zhang H, Liu Y, Wang W, Ren X, Zheng H, Kimmelman AC, Paik JH, Lim C, Perry SR, Jiang S, Malinn B, Protopopov A, Colla S, Xiao Y, Hezel AF, Bardeesy N, Turley SJ, Wang YA, Chin L, Thayer SP, DePinho RA. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov 1(2):158-69, 2011. e-Pub 2011. PMID: 21984975.
34. Storti P, Donofrio G, Colla S, Airoldi I, Bolzoni M, Agnelli L, Abeltino M, Todoerti K, Lazzaretti M, Mancini C, Ribatti D, Bonomini S, Franceschi V, Pistoia V, Lisignoli G, Pedrazzini A, Cavicchi O, Neri A, Rizzoli V, Giuliani N. HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients. Leukemia 25(3):527-37, 2011. e-Pub 2010. PMID: 21183939.
35. Sahin E, Colla S, Liesa M, Moslehi J, Müller FL, Guo M, Cooper M, Kotton D, Fabian AJ, Walkey C, Maser RS, Tonon G, Foerster F, Xiong R, Wang YA, Shukla SA, Jaskelioff M, Martin ES, Heffernan TP, Protopopov A, Ivanova E, Mahoney JE, Kost-Alimova M, Perry SR, Bronson R, Liao R, Mulligan R, Shirihai OS, Chin L, DePinho RA. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 470(7334):359-65, 2011. e-Pub 2011. PMID: 21307849.
36. Abeltino M, Bonomini S, Bolzoni M, Storti P, Colla S, Todoerti K, Agnelli L, Neri A, Rizzoli V, Giuliani N. The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol 39(1):55-65, 2011. e-Pub 2010. PMID: 20977926.
37. Gan B, Hu J, Jiang S, Liu Y, Sahin E, Zhuang L, Fletcher-Sananikone E, Colla S, Wang YA, Chin L, Depinho RA. Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature 468(7324):701-4, 2010. PMID: 21124456.
38. Colla S, Storti P, Donofrio G, Todoerti K, Bolzoni M, Lazzaretti M, Abeltino M, Ippolito L, Neri A, Ribatti D, Rizzoli V, Martella E, Giuliani N. Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia 24(11):1967-70, 2010. e-Pub 2010. PMID: 20811474.
39. Giuliani N, Lisignoli G, Novara F, Storti P, Zaffaroni N, Villa R, Sammarelli G, Agnelli L, Todoerti K, Bernardo ME, Manferdini C, Colla S, Abeltino M, Bolzoni M, Rocci A, Gabusi E, Palumbo A, Zuffardi O, Neri A, Rizzoli V. Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients. Leukemia 24(7):1368-70, 2010. e-Pub 2010. PMID: 20485369.
40. Todoerti K, Lisignoli G, Storti P, Agnelli L, Novara F, Manferdini C, Codeluppi K, Colla S, Crugnola M, Abeltino M, Bolzoni M, Sgobba V, Facchini A, Lambertenghi-Deliliers G, Zuffardi O, Rizzoli V, Neri A, Giuliani N. Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Exp Hematol 38(2):141-53, 2010. e-Pub 2009. PMID: 19963035.
41. Airoldi I, Cocco C, Giuliani N, Ferrarini M, Colla S, Ognio E, Taverniti G, Di Carlo E, Cutrona G, Perfetti V, Rizzoli V, Ribatti D, Pistoia V. Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target. Blood 112(3):750-9, 2008. e-Pub 2008. PMID: 18474725.
42. Giuliani N, Lisignoli G, Colla S, Lazzaretti M, Storti P, Mancini C, Bonomini S, Manferdini C, Codeluppi K, Facchini A, Rizzoli V. CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions. Cancer Res 68(16):6840-50, 2008. PMID: 18703490.
43. Colla S, Tagliaferri S, Morandi F, Lunghi P, Donofrio G, Martorana D, Mancini C, Lazzaretti M, Mazzera L, Ravanetti L, Bonomini S, Ferrari L, Miranda C, Ladetto M, Neri TM, Neri A, Greco A, Mangoni M, Bonati A, Rizzoli V, Giuliani N. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood 110(13):4464-75, 2007. e-Pub 2007. PMID: 17848618.
44. Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, Barlogie B, Shaughnessy JD. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood 109(11):4995-5001, 2007. e-Pub 2007. PMID: 17303695.
45. Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O, Yaccoby S, Epstein J, Barlogie B, Shaughnessy JD. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood 109(10):4470-7, 2007. e-Pub 2007. PMID: 17255354.
46. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109(6):2276-84, 2007. e-Pub 2006. PMID: 17105813.
47. Giuliani N, Bonomini S, Romagnani P, Lazzaretti M, Morandi F, Colla S, Tagliaferri S, Lasagni L, Annunziato F, Crugnola M, Rizzoli V. CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica 91(11):1489-97, 2006. PMID: 17082008.
48. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD. The molecular classification of multiple myeloma. Blood 108(6):2020-8, 2006. e-Pub 2006. PMID: 16728703.
49. Colla S, Morandi F, Lazzaretti M, Rizzato R, Lunghi P, Bonomini S, Mancini C, Pedrazzoni M, Crugnola M, Rizzoli V, Giuliani N. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia 19(12):2166-76, 2005. PMID: 16208410.
50. Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, Grano M, Colucci S, Svaldi M, Rizzoli V.. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Haematologica 90(2):275-8, 2005. e-Pub 2005. PMID: 15710592.
51. Ehrlich LA, Chung HY, Ghobrial I, Choi SJ, Morandi F, Colla S Rizzoli V, Roodman GD, Giuliani N. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 106(4):1407-14, 2005. e-Pub 2005. PMID: 15878977.
52. Giuliani N, Colla S, Morandi F, Rizzoli V. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment. Haematologica 89(9):1118-23, 2004. PMID: 15377473.
53. Giuliani N, Lunghi P, Morandi F, Colla S, Bonomini S, Hojden M, Rizzoli V, Bonati A. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia 18(3):628-35, 2004. PMID: 14737074.
54. Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C, Bonomini S, Lunghi P, Hojden M, Genestreti G, Svaldi M, Coser P, Fattori PP, Sammarelli G, Gazzola GC, Bataille R, Almici C, Caramatti C, Mangoni L, Rizzoli V. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 102(2):638-45, 2003. e-Pub 2003. PMID: 12649156.
55. Giuliani N, Caramatti C, Roti G, Geata A, Colla S, Bonomini S, Hojden M, La Monica S, Sammarelli G, Lazzaretti M, Craviotto L, Mangoni L, Rizzoli V. Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes. J Clin Oncol 21(9):1887-8, 2003. PMID: 12721268.
56. Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S, Bonomini S, Hojden M, Sammarelli G, Barillè S, Bataille R, Rizzoli V. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100(13):4615-21, 2002. e-Pub 2002. PMID: 12393684.
57. Cilloni D, Carlo-Stella C, Falzetti F, Sammarelli G, Regazzi E, Colla S, Rizzoli V, Aversa F, Martelli MF, Tabilio A. Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation. Blood 96(10):3637-43, 2000. PMID: 11071665.
58. Fogli M, Carlo-Stella C, Curti A, Ratta M, Tazzari PL, Ragazzi E, Colla S, Santucci AM, Tura S, Lemoli RM. Transforming growth factor beta3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis. Exp Hematol 28(7):775-83, 2000. PMID: 10907639.
59. Carlo-Stella C, Regazzi E, Sammarelli G, Colla S, Garau D, Gazit A, Savoldo B, Cilloni D, Tabilio A, Levitzki A, Rizzoli V. Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells. Blood 93(11):3973-82, 1999. PMID: 10339507.

Invited Articles

1. Rodriguez-Sevilla JJ, Adema V, Garcia-Manero G, Colla S. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation. Cell Rep Med 4(2):100940, 2023. e-Pub 2023. PMID: 36787738.
2. Ganan-Gomez I, Clise-Dwyer K, Colla S. Isolation, culture, and immunophenotypic analysis of bone marrow HSPCs from patients with myelodysplastic syndromes. STAR Protoc 3(4):101764, 2022. e-Pub 2022. PMID: 36240061.
3. Fiorini E, Santoni A, Colla S. Dysfunctional telomeres and hematological disorders. Differentiation 100:1-11, 2018. e-Pub 2018. PMID: 29331736.
4. Gañán-Gómez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS, Verma A, Steidl U, Garcia-Manero G. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia 29(7):1458-69, 2015. e-Pub 2015. PMID: 25761935.
5. Giuliani N, Colla S, Morandi F, Rizzoli V. Angiopoietin-1 and myeloma-induced angiogenesis. Leuk Lymphoma 46(1):29-33, 2005. PMID: 15621778.
6. Giuliani N, Colla S, Rizzoli V. Update on the pathogenesis of osteolysis in multiple myeloma patients. Acta Biomed 75(3):143-52, 2004. PMID: 15796087.
7. Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol 32(8):685-91, 2004. PMID: 15308315.
8. Colla S, Sammarelli G, Crugnola M, Ascani S, Sabbatini E, Bonomini S, Hojden M, Craviotto L, De Celis I, Morandi F, Caramatti C, Rizzoli V, Giuliani N. Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia. Eur J Haematol 72(5):361-5, 2004. PMID: 15059073.
9. Giuliani N, Colla S, Rizzoli V. Angiogenic switch in multiple myeloma. Hematology 9(5-6):377-81, 2004. PMID: 15763977.

Editorials

1. Marchesini M, Fiorini E, Colla S. RNA processing: a new player of genomic instability in multiple myeloma. Oncoscience 4(7-8):73-74, 2017. PMID: 28966938.

Abstracts

1. Bolzoni M, Colla S, Storti P, Donofrio G, Abeltino M, Sgobba V, Bonomini S, Rizzoli V, Giuliani N. Myeloma Cells Inhibit the Non-Canonical Wnt Co-Receptor Ror2 in Human Mesenchymal/Osteoprogenitor Cells: Effect of Wnt5a/Ror2 Pathway Activation On MM-Induced Impairment of the Osteogenic Differentiation Process. Blood 114(11):741, 2009.
2. Giuliani N, Novara F, Todoerti K, Zaffaroni N, Villa R, Storti P, Ester Bernardo M, Manferdini C, Gabusi E, Abeltino M, Bolzoni M, Agnelli L, Rocci A, Colla S, Sammarelli G, Rizzoli V, Zuffardi O, Neri A, Lisignoli G. Are the Myeloma Bone Microevironment Cells Tumoral or Not?. Blood 114(11):1816, 2009.
3. Giuliani N, Colla S, Storti P, Sgobba V, Todoerti K, Donofrio G, Bolzoni M, Abeltino M, Lazzaretti M, Bonomini S, Crugnola M, Neri A, Rizzoli V. Oxygen Tension in the Bone Marrow (BM) of Patients with Malignant and Indolent Monoclonal Gammopathy: Role of Hypoxia and Hypoxia-Inducible Factor (HIF)-1 in the Regulation of Gene Expression and Pro-Angiogenic Profiles of CD138+ Cells. Blood 114(11):422, 2009.
4. Storti P, Donofrio G, Bolzoni M, Colla S, Airoldi I, Sgobba V, Abeltino M, Todoerti K, Agnelli L, Lazzaretti M, Mancini C, Bonomini S, Ribatti D, Pistoia V, Neri A, Rizzoli V, Giuliani N. HOXB7 Is Critically Involved in Multiple Myeloma-Induced Angiogenic Switch. Blood 114(11):125, 2009.
5. Giuliani N, Colla S, Storti P, Donofrio G, Bolzoni M, Bonomini S, Galla L, Sammarelli G, Mangoni M, Rizzoli V. Activation of Non-Canonical Wnt Pathway in Human Mesenchymal Cells Affects Osteogenic Differentiation: A Potential Target in Multiple Myeloma Microenvironment. Blood 112(11):2742, 2008.
6. Colla S, Giuliani N, Storti P, Lazzaretti M, Todoerti K, Lisignoli G, Agnelli L, Manferdini C, Bonomini S, Galla L, Bolzoni M, Mancini C, Sammarelli G, Mangoni M, Lambertenghi Deliliers G, Neri A, Rizzoli V. HOXB7 Overexpression in Mesenchymal Cells Stimulates the Production of Pro-Angiogenic Molecules: Potential Role in Multiple Myeloma Associated Angiogenesis. Blood 112(11):2743, 2008.
7. Colla S, Storti P, Donofrio G, Lazzaretti M, Bonomini S, Lunghi P, Crugnola M, Bolzoni M, Galla L, Ippolito L, Martella E, Sammarelli G, Craviotto L, Caramatti C, Mangoni M, Bonati A, Rizzoli V, Giuliani N. Hypoxia and Hypoxia Inducible Factor (HIF)-1 in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment. Blood 112(11):1687, 2008.
8. Giuliani N, Lisignoli G, Tagliaferri S, Lazzaretti M, Morandi F, Colla S, Manferdini C, Tonnarelli B, Rizzoli V. Protein (MIP)-3a/CCL20 and Its Receptor CCR6 Are Overexpressed in the Bone Microenvironment and Involved in Osteoclast Formation in Multiple Myeloma Patients. Blood 110(11):3510, 2007. e-Pub 2007.
9. Giuliani N, Todoerti K, Lisignoli G, Tagliaferri S, Agnelli L, Morandi F, Colla S, Crugnola M, Magnani M, Caramatti C, Mangoni M, Lambertenghi Deliliers G, Rizzoli V, Neri A. Gene Expression Profiling of Isolated Mesenchymal and Osteoblastic Cells Exhibits a Different Pattern of Expression in Multiple Myeloma Patients as Compared to Healthy Subjects: Potential Relationship with the Presence of Bone Lesions. Blood 110(11):3513, 2007.

Letters to the Editor

1. Giuliani N, Morandi F, Tagliaferri S, Colla S, Bonomini S, Sammarelli G, Rizzoli V. Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients. Blood 107: 841-2, 2006.
2. Colla S, Sammarelli G, Voltolini S, Crugnola M, Sebastio P, Giuliani N. e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?. Haematologica 89: 611-3, 2004.
3. Giuliani N, Colla S, Rizzoli V, Barillé-Nion S, Bataille R. Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?. Cancer Res 64: 772-3; author reply 774-5, 2004.
4. Colla S, Morandi F, Lazzaretti M, Polistena P, Svaldi M, Coser P, Bonomini S, Hojden M, Martella E, Chisesi T, Rizzoli V, Giuliani N. Do human myeloma cells directly produce basic FGF?. Blood 102: 3071-2; author reply 3072-3, 2003.
5. Colla S, Roti G, Rizzoli V, Giuliani N. Angiopoietins expression by human myeloma cells. Haematologica 88: ELT20; author reply ELT21, 2003.